BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38412399)

  • 41. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
    Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topical non-occlusive polymers in hand-foot syndrome.
    Fabbrocini G; Cristaudo A; Ionescu MA; Panariello L; Robert G; Pellicano M; Ayala F
    G Ital Dermatol Venereol; 2018 Apr; 153(2):165-171. PubMed ID: 29564873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topical NSAIDs for chronic musculoskeletal pain in adults.
    Derry S; Conaghan P; Da Silva JA; Wiffen PJ; Moore RA
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD007400. PubMed ID: 27103611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
    Janssen JM; Jacobs BAW; Roosendaal J; Derissen EJB; Marchetti S; Beijnen JH; Huitema ADR; Dorlo TPC
    AAPS J; 2021 Jan; 23(1):23. PubMed ID: 33417061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
    Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
    Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.
    Kuehl K; Carr W; Yanchick J; Magelli M; Rovati S
    Int J Sports Med; 2011 Aug; 32(8):635-43. PubMed ID: 21563042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
    Martín M; Martínez N; Ramos M; Calvo L; Lluch A; Zamora P; Muñoz M; Carrasco E; Caballero R; García-Sáenz JÁ; Guerra E; Caronia D; Casado A; Ruíz-Borrego M; Hernando B; Chacón JI; De la Torre-Montero JC; Jimeno MÁ; Heras L; Alonso R; De la Haba J; Pita G; Constenla M; González-Neira A
    Oncologist; 2015 Feb; 20(2):111-2. PubMed ID: 25601966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
    Kwakman JJM; Simkens LHJ; van Rooijen JM; van de Wouw AJ; Ten Tije AJ; Creemers GJM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; van Werkhoven E; Punt CJA
    Ann Oncol; 2017 Jun; 28(6):1288-1293. PubMed ID: 28383633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.
    Anderson RT; Keating KN; Doll HA; Camacho F
    Oncologist; 2015 Jul; 20(7):831-8. PubMed ID: 26084809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
    Riff DS; Duckor S; Gottlieb I; Diamond E; Soulier S; Raymond G; Boesing SE
    Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
    J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
    Zhao J; Zhang X; Cui X; Wang D; Zhang B; Ban L
    Oncol Res; 2020 Feb; 28(1):103-106. PubMed ID: 31558182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis.
    Simon LS; Grierson LM; Naseer Z; Bookman AAM; Shainhouse ZJ
    Pain; 2009 Jun; 143(3):238-245. PubMed ID: 19380203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial.
    Roth SH; Shainhouse JZ
    Arch Intern Med; 2004 Oct; 164(18):2017-23. PubMed ID: 15477437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical NSAIDs for chronic musculoskeletal pain in adults.
    Derry S; Moore RA; Rabbie R
    Cochrane Database Syst Rev; 2012 Sep; 9(9):CD007400. PubMed ID: 22972108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.